Pfizer Inc (NYSE:PFE) Announces Results Of Two Phase-III Clinical Trials
Last week, Pfizer Inc. (NYSE:PFE) announced top line results from 2 different Phase-III clinical trials of the novel oral Janus kinase-inhibitor, tofacitinib. This is being investigated to be used for treating adults who suffer from moderate to severe chronic plaque-psoriasis. These are the first 2 of the 5 different studies that are part of the Phase-III OPT Program. This is one of the most extensive global clinical-trails that is being conducted to investigate moderate to severe chronic-plaque psoriasis, to date.
The results for these trials are expected to come in by the 2014 Q2. These 4 studies along with the long term extension-study will be the strong base for the potential psoriasis-submission to the regulatory authorities.
In Friday’s trading, Pfizer Inc (NYSE:PFE) dropped by 0.17%. The shares opened at a price of $28.92, which rose to an intraday high of $28.93 and dropped to a close of $28.72. Approximately 24.40M shares were traded on Friday while an average volume of 25.04 million shares were traded over a period of 30 days. The 52-week low of Pfizer Inc (NYSE:PFE) shares is $23.55 and its 52-week high is $31.15. Pfizer Inc (NYSE:PFE) has a market capitalization of $190.14 billion.
About the company
Pfizer Inc (NYSE:PFE) is a research based, global bio-pharma company. It has five operating segments – 1) Primary Care; 2) Specialty Care and Oncology;3) Established Products and Emerging Markets; 4) Animal Health and Consumer Healthcare, and 5) Nutrition. Its diversified global-healthcare portfolio includes various human & animal biologic and small-molecule vaccines and medicines. It also includes nutritional products and consumer-healthcare products. The Animal Health business-unit is involved in discovering, developing and selling products that are used in the treatment and prevention of diseases in companion animals and livestock. On 1 August 2011, Pfizer Inc (NYSE:PFE) completed its Capsugel business-sale.